Albion Drug Discovery Services Ltd

In my 8th quarterly review of clinical ion channel drug development there is mixed news from a varied portfolio of peripheral and CNS small molecule and gene therapy programs targeting cardiac and musculo-skeletal indications, pain, hearing loss and blindness, epilepsy and depression. There are mixed updates on several programs I covered in previous blogs, as well as several high profile M&A and collaborations in the CNS space (BMS & Karuna, Merck & Caraway, Abbvie & Cerevel, Jazz & Autifony). This report includes updates on progress for a range of new and old ion channel targets including neuronal voltage-gated Nav1.2, Nav1.6, Nav1.8 and Kv7.x channels, SK and CLC1 muscle channels, ENaC epithelial channels, lysosomal TMEM175 and TRPML1 channels, and ligand-gated P2X, TRPA1 and CNS GABA-A and NMDA receptors. #ionchannels #drugdiscovery #painmedicine #epilepsy #cysticfibrosis #retina #hearingloss #raredisease #biotech #pharma AbbVie Acesion Pharma Acousia Therapeutics GmbH Alto Neuroscience Autifony Therapeutics Bristol Myers Squibb Boehringer Ingelheim Bsense Bio Therapeutics Ltd Caraway Therapeutics, Inc. Cerevel Therapeutics Eli Lilly and Company Jazz Pharmaceuticals Johnson & Johnson Karuna Therapeutics Kiora Pharmaceuticals, Inc. Merck Group MSD Neurocrine Biosciences NMD Pharma A/S Praxis Precision Medicines, Inc. Saniona WEX Pharmaceuticals Inc. Xenon Pharmaceuticals Inc.

𝗖𝗵𝗮𝗻𝗻𝗲𝗹𝗼𝗽𝗮𝘁𝗵𝘆 𝗣𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴: 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗶𝗻 𝗜𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 In his latest blog, Marc Rogers examines the significant impact of high-throughput automated patch clamp (APC) technology in ion channel drug discovery. With the surge in genetic screening for common, rare, and undiagnosed diseases, channelopathies—disease-related mutations in ion channels—are becoming increasingly vital to understand. APC plays a key role in rapidly characterizing the biophysical and pharmacological properties of these mutations, thus enhancing our ability to link genetic variations to patient outcomes and clinical treatments. This blog, explores the critical role of APC in profiling mutations across a spectrum of channels and receptors, including cardiac and neuronal voltage-gated Nav and Cav channels, and compares it with other characterization methods like evolutionary analysis and atomistic models. Marc also discusses translational case studies that validate the biophysical predictions of channelopathies in human cells, setting a new standard for ion channel research and treatment. Join us as we explore how APC is advancing precision medicine in ion channel drug discovery. For more insights, read the full article on our blog: https://ow.ly/zk9M50SVQZP #IonChannels #DrugDiscovery #Channelopathies #APC #AutomatedPatchClamp #Electrophysiology #GeneticScreening

Stoked to be heading stateside again, this time to Nanion Technologies 'Membrane Physiology' symposium in Napa, California. Looking forward to hearing about all sorts of ion channel R&D, and catching up with old and new colleagues! https://lnkd.in/e56zDU-8 #ionchannels #drugdiscovery #collaboration

Hear from last year’s attendees and see why you can't miss the Cure CLCN4 Scientific Conference 2024! 🔥 Register for free for both in-person and online attendance. Click the link to join us: https://lnkd.in/dNbzf-SA #cureclcn4 #cureclcn4conference and a big thank you to Marc Rogers for his support! ✨

I'm pleased to reveal one of the projects I've been working on this quarter - a review article on "Using Automated Patch Clamp Electrophysiology Platforms in Ion Channel Drug Discovery: An Industry Perspective" which has just been published in the journal Expert Opinion on Drug Discovery. A limited # of free copies are available for download by following this link: https://lnkd.in/e-GH2bGs This was a collaborative effort with my colleagues Ali Obergrussberger, Artem Kondratskyi and Niels Fertig. Like me, some of you may feel there is a surfeit of review articles, so we tried to make this overview as topical as possible and focused on recent APC articles and applications (2020 onwards) to highlight the current and near-future uses of this technology for ion channel drug discovery, such as channelopathy variant profiling, characterisation of native and iPSC neurons and cardiomyocytes by voltage and current clamp, and recordings of ion channels in organelles such as TMEM175 and TRPML1 which are very 'hot' topics for neurodegeneration. We also compiled my quarterly blogs on ion channel ligands in clinical development to create what we hope is a useful Table of the current state-of-play in ion channel drug discovery.

In my 7th quarterly review of ion channel drug clinical development there is positive news from a varied portfolio of peripheral and CNS small molecule and gene therapy programs targeting cardiac, musculo-skeletal, pain, epilepsy, depression and neuropsychiatric indications, as well as a notable failure of a TRPA1 pain drug. Steady progress is being made in CNS projects I have highlighted in past updates from the likes of Biohaven, Praxis Precision Medicines and Stoke Therapeutics, as well as several licensing deals and collaborations involving established players and some new names. This report includes updates on progress for a range of new and old ion channel targets including Nav1.x, Cav3.x, Kv7.x voltage-gated channels, SK and K2P THIK1 channels, and ligand-gated TRPV1, TRPA1, GABA-A and NMDA receptors. #ionchannels #drugdiscovery #cns #painmedicine #epilepsy #cysticfibrosis #depression #neuromuscular #neurodegeneration #neuroinflammation #atrialfibrillation #cardiac #covid19 #cough #aso Actio Biosciences, Inc. Acesion Pharma Arialys Therapeutics, Inc. ARMGO Pharma, Inc. AstronauTx Axxam Biogen Biohaven Biotron Ltd Breye Therapeutics ApS Cerevance Eli Lilly and Company Genentech Golgi Neurosciences S.r.l. Marinus Pharma Milestone Pharmaceuticals, Inc. NMD Pharma A/S Novartis Praxis Precision Medicines, Inc. Quiver Bioscience ReCode Therapeutics Relmada Therapeutics, Inc Sage Therapeutics Saniona Stoke Therapeutics uniQure Vistagen

In my 6th quarterly review of clinical ion channel drug development there is positive news from a varied portfolio of CNS and peripheral disease programs targeting cough, pain, epilepsy and neuromuscular indications. Steady progress is being made in projects I have highlighted in past updates from the likes of Praxis Precision Medicines and Stoke Therapeutics, as well as several significant out-licensing and M&A deals from established players (e.g. Bellus Health's P2X3 cough drug), and involvement of some new names. This report includes updates on progress for a range of new and old ion channel targets including Nav1.x, Cav2.3 and Cav3.x, Kv3.x and Kv7.x voltage-gated channels, and ligand-gated TRPV1 and P2X receptors. #ionchannels #drugdiscovery #epilepsy #pain #cough #raredisease